The SUPPORT Act: America’s Biggest Opioid Law Explained

Last updated 4 days ago. Our resources are updated regularly but please keep in mind that links, programs, policies, and contact information do change.

In the fall of 2018, as the United States grappled with an opioid crisis claiming tens of thousands of lives annually, Congress passed legislation so vast and comprehensive that President Donald Trump called it the “single largest bill to combat the drug crisis in the history of our country.”

The bill, officially known as the Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act, or the SUPPORT for Patients and Communities Act, was a rare example of bipartisanship. It passed through the House of Representatives with a vote of 393-8 and the Senate by 98-1 before being signed into law.

The SUPPORT Act represented a monumental shift in the federal government’s strategy. Building on prior laws like the Comprehensive Addiction and Recovery Act (CARA) of 2016 and the 21st Century Cures Act, it moved beyond piecemeal grants and enforcement actions to rewire the nation’s healthcare, regulatory, and public health systems to confront the epidemic.

How the SUPPORT Act Changed Healthcare

The core of the SUPPORT Act was its recognition that the opioid crisis had grown too large to be managed by grant-funded programs alone. It required the systemic financial power of America’s largest public health insurance programs: Medicaid and Medicare. The law’s most transformative provisions repurposed these massive systems, turning them into the primary engines for expanding access to addiction treatment across the country.

Medicaid: Insuring the Most Vulnerable

With Medicaid serving as the single largest payer for substance use disorder (SUD) treatment in the nation—covering nearly four in ten adults with an opioid use disorder (OUD)—it was the logical starting point for any large-scale federal intervention. The SUPPORT Act made several groundbreaking changes to how the program operates.

Mandatory Medication-Assisted Treatment

Perhaps the most critical healthcare provision in the act was a five-year mandate requiring all state Medicaid programs to cover every FDA-approved medication for opioid use disorder—buprenorphine, methadone, and naltrexone—along with related counseling and behavioral therapy. This was a landmark step.

MAT is widely considered the “gold standard” of care for OUD, and numerous studies have shown that it dramatically reduces the risk of fatal overdose, in some cases by more than 75%. By making this coverage a national requirement, the law aimed to eliminate geographic disparities in access to the most effective life-saving treatments.

Breaking the IMD Exclusion

For decades, a federal rule known as the Institutions for Mental Diseases (IMD) exclusion prohibited Medicaid from paying for care in residential mental health or substance use treatment facilities with more than 16 beds for adults aged 21-64. This policy effectively locked Medicaid enrollees out of thousands of inpatient treatment beds.

The SUPPORT Act created a crucial, albeit temporary, workaround. It gave states a five-year option (from October 2019 to September 2023) to use federal Medicaid funds to cover up to 30 days of care per year in an IMD for patients with a SUD. This single provision was the most expensive in the entire bill, with the Congressional Budget Office (CBO) estimating its cost at over $1 billion over ten years.

The American Hospital Association (AHA) lauded this change, noting how impactful the flexibility has been for ensuring patients receive care in the most clinically appropriate setting.

Continuity of Care for Youth

The law also addressed a critical failure point in the justice system. Previously, when a young person entered a juvenile detention facility, their Medicaid coverage was often terminated, forcing them to go through a lengthy and complicated re-enrollment process upon release. This created a dangerous gap in care at the precise moment their overdose risk was highest.

Research shows individuals leaving incarceration are up to 40 times more likely to die from an overdose than the general population. The SUPPORT Act implemented a simple but profound administrative change: it prohibited states from terminating Medicaid for incarcerated individuals under 21 or former foster youth up to age 26. Instead, states were required to suspend coverage and automatically restore it upon release, ensuring a seamless transition back to community-based care.

State Innovation Grants

Recognizing that provider shortages were a major barrier to care, Section 1003 of the Act authorized $50 million for planning grants to at least 10 states. These grants were intended to help states develop innovative strategies to increase their SUD provider capacity, particularly for MAT. Following the planning phase, up to five of these states were selected to receive enhanced federal matching funds to implement their plans, providing a powerful financial incentive to build out their treatment infrastructure.

Medicare: Adapting Senior Care

The opioid crisis is not limited to younger populations; it has also taken a heavy toll on Medicare beneficiaries, many of whom live with chronic pain. The SUPPORT Act introduced several key reforms to modernize the Medicare program and equip it to better identify and treat SUD among its enrollees.

Telehealth Expansion

In a forward-looking move that proved essential during the subsequent COVID-19 pandemic, Section 2001 of the Act removed long-standing geographic restrictions that had limited Medicare reimbursement for telehealth services to rural areas. Effective July 1, 2019, Medicare beneficiaries across the country could receive SUD and mental health treatment via telehealth from their own homes. This provision dramatically expanded access to care, particularly for individuals with mobility issues or those living in areas with few specialized providers.

SUD Screening in Routine Care

To promote earlier detection and intervention, the Act mandated that the initial “Welcome to Medicare” physical exam and subsequent annual wellness visits include a screening for potential substance use disorders and a review of any current opioid prescriptions. This integrated SUD screening into routine preventive care, helping to normalize the conversation around addiction and identify at-risk individuals before a crisis occurs.

Fighting Overprescribing and Fraud

The law took several steps to tighten controls on opioid prescribing within the Medicare Part D prescription drug program. It mandated the use of electronic prescribing for all controlled substances by 2021 to reduce errors and fraudulent paper prescriptions. It also required all Part D plans to establish “lock-in” programs, which limit beneficiaries identified as being at high risk for abuse to using specific prescribers or pharmacies.

Furthermore, the Centers for Medicare & Medicaid Services (CMS) was directed to identify and formally notify physicians who are statistical “outliers” in their opioid prescribing patterns compared to their peers.

Methadone Clinic Coverage

In a major expansion of benefits, the SUPPORT Act authorized Medicare coverage for services provided in Opioid Treatment Programs (OTPs), commonly known as methadone clinics, for the first time. Previously, Medicare beneficiaries often had to pay out-of-pocket for this intensive form of treatment. The Act created a new bundled payment system for OTPs, covering the cost of medications, counseling, and toxicology testing, thereby filling a critical gap in the continuum of care for seniors and people with disabilities struggling with OUD.

Controlling the Drug Supply

The SUPPORT Act’s strategy extended beyond expanding treatment; it also aimed to shrink the supply of both diverted prescription drugs and illicit synthetic opioids flooding into the country. This involved a two-front approach: empowering federal agencies like the FDA and DEA with new regulatory tools and equipping law enforcement to disrupt the criminal enterprises profiting from the crisis.

FDA’s New Role

The Act tasked the Food and Drug Administration (FDA) with taking a more proactive role in preventing addiction and diversion at the source.

Fostering Non-Addictive Pain Alternatives: Recognizing the need for better pain management options, the law directed the FDA to issue guidance to help drug manufacturers navigate the development and approval process for new, non-addictive pain treatments.

Safer Packaging and Disposal: A subtitle of the law, the SOUND Disposal and Packaging Act, gave the FDA new authority to require that certain opioids be sold in special packaging, such as unit-dose blister packs for a three- or seven-day supply, to prevent the accumulation of leftover pills. It also encouraged the development of novel, in-home disposal methods to make it easier for patients to safely get rid of unused medications.

Post-Market Scrutiny: The law empowered the FDA to require drug companies to conduct post-approval studies to assess how a drug is being used in the real world and whether its effectiveness is being undermined by widespread abuse and diversion.

The STOP Act: Targeting Fentanyl

A major legislative achievement within the SUPPORT Act was the Synthetics Trafficking and Overdose Prevention (STOP) Act. The STOP Act was a direct response to the explosion of illicit fentanyl being shipped from overseas, primarily China, directly to American buyers through the international mail system.

It required the U.S. Postal Service to obtain advance electronic data—such as the sender’s and recipient’s names and addresses—on all incoming international packages. This data allows U.S. Customs and Border Protection to use advanced analytics to better target suspicious packages for inspection and seizure, attacking the logistics model that had allowed traffickers to operate with near-anonymity.

Fighting Recovery Fraud

At the same time the STOP Act targeted international supply chains, the Eliminating Kickbacks in Recovery Act (EKRA) targeted a corrupt domestic business model that had emerged alongside the treatment boom. Codified in federal criminal law (18 U.S.C. § 220), EKRA made it illegal for anyone to solicit, receive, or pay any remuneration for referrals to recovery homes, clinical treatment facilities, or laboratories.

This provision was aimed squarely at “patient brokers,” who preyed on vulnerable individuals with SUD by “selling” them to the highest-bidding treatment center, often leading to fraudulent billing, poor quality care, and patient relapse.

DEA Manufacturing Quotas

In a significant philosophical shift for drug regulation, the SUPPORT Act changed how the Drug Enforcement Administration (DEA) sets its annual manufacturing quotas for controlled substances. For decades, these quotas were based primarily on industry estimates of legitimate medical need.

Section 3282 of the Act legally required the DEA, for the first time, to also consider public health data, including rates of “overdose deaths and abuse,” when determining how much of a given opioid can be legally produced in the United States. This provision legally connected the administrative act of setting a production number to its real-world consequences, forcing a law enforcement agency to incorporate a public health perspective into its supply-side calculations.

Building Community Infrastructure

The architects of the SUPPORT Act understood that while federal funding and regulation are essential, the day-to-day work of helping people find and sustain recovery happens at the local level. Consequently, the law invested heavily in building the on-the-ground infrastructure—the workforce, facilities, and community networks—needed to create a durable, long-term response to the addiction crisis.

Addressing Workforce Shortages

A major barrier to treatment has long been a severe shortage of qualified addiction specialists. To address this, Section 7071 of the Act created a loan repayment program that offers to pay off student debt for individuals who commit to working in a substance use disorder treatment job in a designated mental health professional shortage area or a county with a particularly high rate of overdose deaths. This created a powerful incentive for new graduates to enter the field and practice where they are needed most.

The law also permanently authorized physician assistants and nurse practitioners to prescribe MAT and temporarily extended this authority to other providers like clinical nurse specialists and certified nurse midwives, expanding the pool of available prescribers.

Recovery Infrastructure

The law’s provisions reflect a modern understanding of SUD as a chronic condition that requires long-term management, not just an acute intervention. It authorized the Substance Abuse and Mental Health Services Administration (SAMHSA) to award grants for the creation of Comprehensive Opioid Recovery Centers (CORCs), designed to provide a full continuum of services, including employment support, housing assistance, and long-term recovery coaching.

The Act also funded programs to help states develop and implement best practices for recovery housing, providing safe, substance-free living environments for people transitioning out of treatment. Crucially, it also increased funding for peer-led “Communities of Recovery” organizations, which leverage the expertise of people with lived experience to support others on their recovery journey.

Supporting Families and Children

The SUPPORT Act included targeted provisions to address the devastating impact of the crisis on children and families. It authorized new funding and directed the Department of Health and Human Services (HHS) to issue guidance on improving care for pregnant and postpartum women with SUD and for infants born with neonatal abstinence syndrome (NAS). It also allowed state Medicaid programs to cover care for these infants in specialized residential pediatric recovery centers.

This focus on perinatal care and early childhood represents a strategic, long-term investment. By intervening at this critical stage, the law aims to mitigate the trauma and health consequences of the crisis for the next generation, potentially breaking intergenerational cycles of addiction.

Furthermore, the Act authorized programs at the Centers for Disease Control and Prevention (CDC) to collect data on and develop responses to adverse childhood experiences (ACEs), recognizing that childhood trauma is a major risk factor for substance misuse later in life.

Five Years Later: Mixed Results

The SUPPORT Act was a landmark legislative response, but its implementation occurred during a period of unprecedented change in the nature of the drug crisis. The law was expertly designed to fight a war against prescription opioids and heroin, but a new, more lethal war against illicitly manufactured fentanyl was already underway.

This shift has complicated assessments of the law’s effectiveness, leading to a mixed record of measured successes, clear challenges, and varied perspectives from those on the front lines.

The Numbers Challenge

When the SUPPORT Act was passed in 2018, the U.S. recorded approximately 70,000 fatal overdoses. By 2023, that number had surged to nearly 110,000, with the vast majority driven not by prescription pills but by illicit fentanyl, often mixed with other substances like xylazine. This new reality, where even casual or first-time drug users are at high risk of a fatal overdose from a poisoned supply, has tested the limits of a law largely focused on reforming the healthcare system and controlling legally manufactured drugs.

Official evaluations of the Act’s programs have been cautious. The Government Accountability Office (GAO), the non-partisan investigative arm of Congress, has conducted several reviews. A July 2025 report on Assisted Outpatient Treatment grants, a related area of focus, found that HHS’s assessments of program outcomes were “inconclusive”. The GAO cited significant methodological challenges, including small sample sizes, inconsistent data collection across states, and an over-reliance on self-reported data, which made it difficult to draw firm conclusions about the programs’ national impact.

Other GAO reports have pointed to implementation delays and data reliability issues at key agencies like the Office of National Drug Control Policy (ONDCP) and SAMHSA, suggesting that the federal government has struggled to effectively track the results of its own initiatives.

These evaluation challenges do not necessarily mean the programs failed, but rather that their effects were difficult to measure scientifically amidst the chaos of a rapidly evolving crisis and a global pandemic. The National Institutes of Health (NIH) noted that the COVID-19 pandemic severely disrupted the implementation of many community-based interventions, making it hard to assess their true potential.

Clear Successes

Despite these broad challenges, there have been clear areas of success. The law’s focus on expanding insurance coverage for treatment has yielded tangible results. Studies in states that expanded Medicaid have shown significant increases in the number of prescriptions filled for life-saving MAT medications like buprenorphine.

The expansion of telehealth for OUD treatment, a key provision of the Act, also proved vital. Research has demonstrated that receiving treatment via telehealth is associated with higher retention in care and a reduced risk of fatal overdose.

What Healthcare Providers Say

Organizations like the American Hospital Association (AHA) have been strong supporters of the Act, consistently advocating for the reauthorization and permanent extension of key provisions. They highlight the flexibility to use Medicaid funds for short-term residential treatment in IMDs and the mandate for Medicaid to cover MAT as critical policies that have allowed them to provide more appropriate and effective care.

At the same time, providers point to persistent challenges that the law did not fully resolve, including chronic underfunding for behavioral health, severe workforce shortages, and the need for better interoperability between state Prescription Drug Monitoring Programs (PDMPs) to allow for seamless data sharing across state lines.

Patient and Advocate Views

Recovery advocacy groups have praised the SUPPORT Act’s investments in community-based services. Patty McCarthy, CEO of Faces & Voices of Recovery, credited the Act’s Building Communities of Recovery Program as a major reason why overdose rates have recently begun to show a slight decline, stating the organization gives its “full-throated support” for the law’s reauthorization.

However, many advocates also view the reauthorization process as a “missed opportunity” to enact bolder reforms that were left out of the original bill. A primary example is the push for the Reentry Act (H.R. 2400/S. 1165), a proposal that would allow Medicaid benefits to be reactivated 30 days before an individual is released from prison or jail. Advocates argue this would provide a critical window to connect individuals with care and MAT before they return to the community, a time of extreme overdose risk. They also point to the lack of comprehensive reform for methadone treatment, which remains highly regulated and difficult to access despite its effectiveness.

Patient advocates for other serious illnesses have also weighed in. The American Cancer Society Cancer Action Network (ACS CAN), for instance, supported the Act’s balanced approach and praised its specific exemptions for cancer and hospice patients, which protect their access to necessary opioid pain medications. However, they also cautioned against states implementing arbitrary prescribing limits that could harm patients with legitimate medical needs.

Law Enforcement Perspective

The SUPPORT Act was passed at a time when law enforcement’s role in the opioid crisis was evolving from one of pure enforcement to that of a public health partner. The law’s provisions have helped support this shift. Police departments across the country are now on the front lines of naloxone distribution and are key partners in diversion programs that offer a pathway to treatment instead of arrest.

However, law enforcement agencies face immense challenges. The sheer lethality and volume of fentanyl have strained resources, while departments nationwide struggle with recruitment and retention. There is also a growing recognition of the need for more robust mental health and wellness support for officers who are routinely exposed to the trauma of responding to overdose scenes.

The Fight for Reauthorization

Many of the SUPPORT Act’s most important provisions were authorized for only five years and expired on September 30, 2023. While Congress has used temporary measures to keep programs funded, the long-term future of this landmark law depends on a complex and increasingly partisan reauthorization process. This legislative fight is not just about extending the original law; it’s about adapting it to the realities of the fentanyl era and deciding whether to embrace even broader reforms.

Congressional Action

Efforts to reauthorize the SUPPORT Act have been underway for several years. In the 118th Congress, the House passed a reauthorization bill, H.R. 4531, with strong bipartisan support. A similar bill, H.R. 2483, passed the House in the 119th Congress in June 2025, again with a wide margin of 366-57.

These bills generally seek to reauthorize key grant programs through fiscal years 2028-2030, increase funding levels for community recovery initiatives and residential treatment for pregnant women, and make the popular Medicaid mandate for MAT coverage permanent.

Adapting to Fentanyl

The reauthorization debate has centered on updating the law to address the current drug landscape. The House-passed bill (H.R. 2483) includes new provisions specifically aimed at the fentanyl crisis, such as establishing a Federal Interagency Work Group on Fentanyl Contamination of Illegal Drugs. It also expands resources for first responders to purchase and use treatments for non-opioid overdoses, a direct response to the increasing prevalence of the veterinary tranquilizer xylazine being mixed with fentanyl.

Political Challenges

The overwhelming consensus that propelled the SUPPORT Act into law in 2018 has begun to fray. While the reauthorization bills still command bipartisan support, the process has become more contentious. During a 2025 committee vote, a number of Democrats voted against the bill they had previously supported. They argued that it was contradictory to reauthorize these vital programs while the administration was simultaneously proposing budget cuts and reorganizations that could undermine the very agencies—like SAMHSA—tasked with implementing them.

This friction suggests that as the opioid crisis transitions from an acute emergency to a long-term, endemic public health challenge, it is becoming entangled in broader, more polarized debates about the size and scope of government, agency funding, and executive authority. The original SUPPORT Act’s success in establishing new principles—such as using Medicaid to ensure continuity of care for justice-involved individuals—has also raised the stakes, empowering advocates to push for more ambitious policies like the Reentry Act.

Our articles make government information more accessible. Please consult a qualified professional for financial, legal, or health advice specific to your circumstances.